Glenmark Pharma’ s entity initiates phase II B human dose range finding trial

Glenmark Pharmecuaticals’ novel chemical entity “Revamilast” has initiated  Phase II B human dose range  finding trial globally. Revamilast is an orally active, potent and selective inhibitor  of phosphodiesterase 4 (PDE 4) that is  currently being developed  by Glenmark for the treatment of chronic  inflammatory disorders such as  Asthma, Rheumatoid Arthritis (RA)  and other inflammatory diseases.

The Phase II studies going to be carried out will help establish the efficacy and safety of the molecule and will also provide dose range finding data for Revamilast.

Glenmark Pharmecuaticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).